drugset / Trial / NCT00536484

Fesoterodine Flexible Dose Study

NCT00536484

Phase 3 Completed 896 enrolled Pfizer
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This Phase 3B study is designed to test if a fesoterodine flexible dose regimen is more effective than placebo in reducing micturition frequency and other overactive bladder (OAB) symptoms, e.g., urgency, urgency incontinence episodes in patients with overactive bladder and if the fesoterodine regimen is safe and well tolerated.

Timeline

Start
2007-08
Primary completion
2008-03
Completion
2008-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Fesoterodine Other / unclassified 4 mg Oral
Subject Fesoterodine Other / unclassified 8 mg Oral

Indications